Anabolic Drugs First for Osteoporosis: Sequencing Therapy for Best Bone Density Gains

“The most effective sequence in almost every situation is to start with an anabolic drug,” said Benjamin Leder, MD, in interviews published on Tuesday.

The question of which osteoporosis drug to prescribe first — and in what order — is moving to the center of clinical debate.

A set of interviews and recent peer-reviewed findings reported by Healio News this week converge on one message: for many patients at high fracture risk, bone-building (anabolic) drugs should come first, not bisphosphonates, the long-standing default. Yet real-world practice still puts bisphosphates first in most cases, and specialists warn the ordering decision can blunt or preserve years of treatment benefit.

“We now have a few medications for osteoporosis that we can use,” Benjamin Leder, MD, professor of medicine at Harvard Medical School, told Healio News | Endocrine Today.

The stakes are fracture risk. Osteoporosis drugs work through two main mechanisms of action: antiresorptive agents such as bisphosphonates — alendronate, risedronate, zoledronic acid — slow bone breakdown, while anabolic agents such as teriparatide, abaloparatide and romosozumab-aqqg actually build bone. Denosumab is classified as an antiresorptive. New evidence reviewed by thesource shows sequencing these drug classes changes outcomes.

Leder, professor of medicine at Harvard Medical School, told Healio News that every available drug has what he considers modest fracture-reduction efficacy, and that usefulness fades over time: “with most of our osteoporosis medications, their efficacy tends to wane the longer you use them.”

Start with bone-building drug then follow with antiresorptive

  • Order matters. Starting with a bone-building drug produces bigger bone-density gains than starting with a bisphosphonate — but only if the anabolic is later followed by an antiresorptive.
  • Don’t stop abruptly. Bone loss returns when treatment stops, fastest after denosumab.
  • A bisphosphonate “holiday” is an option for some patients after 3 to 5 years, but only once fracture risk has come down — and never for patients stopping denosumab without 1 to 2 years of bisphosphonate cover.

Why anabolics first, according to the researchers

E. Michael Lewiecki, MD, of the New Mexico Clinical Research & Osteoporosis Center, said many healthcare professionals struggle to properly follow osteoporosis treatment sequencing, in part due to differences between guidelines. Giving an antiresorptive drug before an anabolic is expected to blunt or delay the bone-building effect — a concern magnified after prolonged or potent antiresorptive therapy.

“if you ever want to use an anabolic drug, it’s best to start it first and it’s essential to follow it with an antiresorptive agent,” Lewiecki told Healio News. The anabolic effect dissipates once the drug stops unless an antiresorptive follows it — a “transition” that locks in gains.

A review of 37 studies in Current Osteoporosis Reports this year found treatment sequences beginning with anabolic drugs produced greater bone mineral density (BMD) increases than bisphosphonate-first step therapy or single-drug treatment. A 2022 study in Osteoporosis International showed romosozumab produced larger BMD gains when used before — rather than after — alendronate or denosumab.

In the DATA-SWITCH extension trial, women who switched from teriparatide to denosumab gained more BMD than those who started with denosumab and switched to teriparatide. Leder was a coauthor of that trial.

Felicia Cosman, MD, professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, said bisphosphonates-first remains the “default” but is the wrong call for patients at very high risk at the outset.

Why practice hasn’t caught up

Two barriers, Cosman told Healio News: insurers that mandate a bisphosphonate course before approving an anabolic — which she said puts doctors and patients in a precarious position because the requirement mitigates the anabolic’s effects — and the fact that all current anabolic drugs are injectable, daily for teriparatide and abaloparatide or monthly for romosozumab, which some patients refuse.

Michael R. McClung, MD, founding and emeritus director of the Oregon Osteoporosis Center, added a practical strain on primary care: bisphosphonates are familiar and easy to prescribe, while injectables require teaching or infusion arrangements. He said bisphosphonates’ pharmacology makes them ideal as maintenance therapy after more potent drugs have done their work.

Guidelines disagree, and unification is underway

Conflicting guidance feeds the confusion. A 2024 position statement from the American Society for Bone and Mineral Research and the Bone Health and Osteoporosis Foundation, coauthored by Lewiecki and Cosman and published in The Journal of Bone and Mineral Research, de-emphasized bisphosphonates as universal first-line therapy and urged individually tailored sequencing. The American College of Physicians’ 2023 guideline, by contrast, recommends bisphosphonates first for most postmenopausal women and men with primary osteoporosis.

Lewiecki offered the numbers behind the tailored approach: with a T-score (a bone-density measure) below –2.7 at the total hip or below –3 at the lumbar spine, alendronate is unlikely to reach the –2.5 treatment target, while denosumab or an anabolic-then-antiresorptive sequence has a higher probability. For the lowest baseline T-scores, he said, romosozumab followed by denosumab offers the greatest probability of crossing that threshold.

Leder told Healio News an effort is underway to harmonize the competing U.S. guidelines — the Endocrine Society and the American Association of Clinical Endocrinology each publish their own.

Drug holidays split the experts too. Reviewers writing in JBMR Plus in 2022 summarized trials and real-world data supporting a bisphosphonate pause after 3 to 5 years in selected patients. Leder said only patients no longer at very high fracture risk are candidates, monitored with bone density testing.

Lewiecki cautioned that some patients still at high risk after five or more years of oral therapy may never be holiday candidates. Cosman stressed that prior therapy changes everything: patients moving off long-term denosumab need 1 to 2 years of bisphosphonate before stopping, whereas 1 to 2 years suffices after estrogen, raloxifene, teriparatide, abaloparatide — and, she said, likely romosozumab.

A review Cosman and Leder coauthored in Endocrine Practice in 2024 found bone loss follows discontinuation of every osteoporosis therapy in clinical trials of postmenopausal women, with the fastest loss after denosumab stops. McClung’s verdict on stopping altogether was blunt: “There is no short-term fix for osteoporosis.”

Drug class Examples in source reporting How it works Key sequencing point
Bisphosphonates Alendronate, risedronate, zoledronic acid Antiresorptive — slows bone breakdown Best suited as maintenance after anabolic therapy
Anabolic agents Teriparatide, abaloparatide, romosozumab-aqqg Bone-building Largest BMD gains when given first; must be followed by an antiresorptive
Other antiresorptive Denosumab Blocks bone resorption Discontinuation triggers the fastest bone loss in trials

Plan bisphosphonate transition before stopping denosumab

The source material carries no universal contraindication list, but it flags who needs specialist attention. Patients on long-term denosumab should never stop without a planned 1 to 2-year bisphosphonate transition; a single bisphosphonate dose is not adequate cover, as Cosman described.

Patients considering a bisphosphonate holiday need bone density testing to confirm that very high fracture risk has resolved, and treatment may restart if BMD declines. Anyone weighing anabolic therapy — particularly those unwilling or unable to manage injections — should discuss sequencing with a clinician familiar with their baseline fracture risk and T-score.

Where sequencing goes next

McClung framed the wider gap: sequencing is only part of the problem, since many patients receive no long-term therapy at all. “If we are to maintain skeletal health over the long run, we need to use different drugs,” he told Healio News. Whether guideline harmonization and payer changes close the anabolics-first gap remains the open question this week’s reporting leaves untested.

References

  • Healio | Endocrine Today — interviews with Benjamin Leder, E. Michael Lewiecki, Felicia Cosman and Michael R. McClung, published November 18, 2026
  • Review of 37 sequencing studies, Current Osteoporosis Reports, 2026
  • Romosozumab sequencing study, Osteoporosis International, 2022
  • DATA-SWITCH extension trial and related switching study, The Journal of Bone and Mineral Research, 2024; ASBMR/Bone Health and Osteoporosis Foundation position statement, The Journal of Bone and Mineral Research, 2024
  • Bisphosphonate drug-holiday review, JBMR Plus, 2022; discontinuation review, Endocrine Practice, 2024

This article is reported coverage of peer-reviewed research and expert interviews and is not medical advice. Treatment decisions belong with a qualified clinician.

Photo of author

Health Desk

Health Desk at Archyde.

How Temple Bar Escaped a Bus Station to Become a €700m Tourist Quarter